Advisory Services Network, LLC Genmab A/S Transaction History

Advisory Services Network, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$27.94 - $35.44 $31,236 - $39,621	1,118 New	1,118 $35,000
Q1 2023 May 17, 2023	BUY	$34.88 - $43.22 $4,360 - $5,402	125 Added 93.98%	258 $9,000
Q4 2022 Feb 13, 2023	BUY	$33.8 - $47.06 $4,495 - $6,258	133 New	133 $5,000
Q3 2021 Nov 05, 2021	SELL	$41.55 - $48.72 $2,285 - $2,679	-55 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$32.88 - $44.57 $1,808 - $2,451	55 New	55 $2,000
Q1 2021 May 24, 2021	SELL	$30.92 - $44.4 $1,700 - $2,442	-55 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$33.66 - $40.76 $25,244 - $30,570	-750 Reduced 93.17%	55 $2,000
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $26,621 - $31,137	805 New	805 $29,000
Q2 2020 Aug 10, 2020	SELL	$20.05 - $33.89 $5,674 - $9,590	-283 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$17.15 - $25.22 $2,143 - $3,152	-125 Reduced 30.64%	283 $6,000
Q4 2019 Feb 04, 2020	BUY	$18.88 - $24.14 $7,703 - $9,849	408 New	408 $9,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.